Neuromuscular rehabilitation interventions and COVID-19 management in a case of incomplete paraplegia with neurogenic bladder, post T3-T5 ependymoma – case report
Keywords:
spinal ependymoma, non-traumatic spinal cord injury, SARS-CoV-2, COVID-19, respiratory rehabilitation, neurological rehabilitationAbstract
INTRODUCTION: Spinal ependymomas are a group of mostly slow-growing tumors that can cause non-traumatic spinal cord injury with insidious clinical symptomatology ranging from neck or back pain to associated sensory-motor impairment. Due to their neurological and systemic frailty, patients with spinal cord injury might be especially vulnerable to the effects of SARS-CoV-2 infection and the resulting respiratory impairment. CASE PRESENTATION: We present the case of a 66 year old women admitted in our Neuromuscular Rehabilitation Clinic Division for severe incomplete paraplegia and neurogenic bladder. She was previously diagnosed in the Neurosurgical Ward with a thoracic grade II (classic) ependymoma and underwent a gross tumor resection. During the neurorehabilitation program the patient was diagnosed with COVID-19. The multi-drug related treatments were associated with supportive oxygen therapy and neuromuscular and respiratory rehabilitation techniques. RESULTS: Despite of the patient’s favorable rehabilitation, consisting of walking abilities with support in a walking frame on short distances, her prognosis may be worsened by resting neurogenic bladder symptoms. COVID-19 has led to important acute respiratory morbidity in our patient, regardless of the mild course of the disease, and might further cause a post-infectious respiratory impairment.
CONCLUSION: Spinal cord injury remains a life-long condition and emphasizes the necessity of supporting the affected patients on the long run.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Mihai Băilă, Aura Spînu, Cristina Popescu, Costică Zamfir, Elena Constantin, Elena Brumă, Cristian Răducanu, Ștefan Adrian Petre, Gelu Onose

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.